Analysis of circulating CD70+lymphocytes and CD70 transcript expression in a phase 1 clinical trial of the CD70-targeting antibody-drug conjugate SGN-75

被引：0
|
作者：
Law, Che-Leung [1 ]
Gordon, Kristine A. [1 ]
Klussman, Kerry [1 ]
Whiting, Nancy C. [1 ]
McEarchem, Julie A. [1 ]
机构：
[1] Seattle Genet Inc, Bothell, WA USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-1284
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1284
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
    Daver, Naval G.
    Erba, Harry P.
    Papadantonakis, Nikolaos
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Konopleva, Marina Y.
    Sloss, Callum M.
    Wang, Jiuzhou
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
  • [42] Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
    Daver, Naval G.
    Montesinos, Pau
    Deangelo, Daniel J.
    Wang, Eunice S.
    Papadantonakis, Nikolaos
    Todisco, Elisabetta
    Sweet, Kendra L.
    Pemmaraju, Naveen
    Lane, Andrew A.
    Torres-Minana, Laura
    Thompson, James E.
    Konopleva, Marina Y.
    Sloss, Callum M.
    Watkins, Krystal
    Bedse, Gaurav
    Du, Yining
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    LANCET ONCOLOGY, 2024, 25 (03): : 388 - 399
  • [43] PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma
    Wang, Lei
    Liu, Haidong
    Shang, Xiao
    Han, Tae
    Zhao, Baiteng
    CANCER RESEARCH, 2022, 82 (12)
  • [44] A phase I. first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies.
    Awada, Ahmad
    Rolfo, Christian D.
    Rottey, Sylvia
    de Lendonck, Laure Ysebrant
    Schroyens, Wilfrled A.
    Offner, Fritz
    Silence, Karen
    Dreier, Torsten
    Moshir, Mahan
    de Heard, Hans
    Posters, Marc
    Bron, Dominique
    Thibault, Alain
    Aftimos, Philippe G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] ROBUST ANTITUMOR ACTIVITY OF THE ANTIBODY-DRUG CONJUGATE SGN-35 WHEN ADMINISTERED EVERY 3 WEEKS TO PATIENTS WITH RELAPSED OR REFRACTORY CD30 POSITIVE HEMATOLOGIC MALIGNANCIES IN A PHASE 1 STUDY
    Younes, A.
    Forero-Torres, A.
    Bartlett, N. L.
    Leonard, J. P.
    Kennedy, D. A.
    Sievers, E. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 205 - 205
  • [46] The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.
    Fanale, Michelle
    Bartlett, Nancy L.
    Forero-Torres, Andres
    Rosenblatt, Joseph
    Horning, Sandra J.
    Franklin, Anna R.
    Lynch, Carmel M.
    Sievers, Eric L.
    Kennedy, Dana A.
    BLOOD, 2009, 114 (22) : 1068 - 1069
  • [47] A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
    Daver, Naval
    Sweet, Kendra L.
    Montesinos, Pau
    Wang, Eunice S.
    Aribi, Ahmed
    DeAngelo, Daniel J.
    Erba, Harry P.
    Martinelli, Giovanni
    Walter, Roland P.
    Altman, Jessica K.
    Advani, Anjali S.
    Curti, Antonio
    Sloss, Callum M.
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    BLOOD, 2020, 136
  • [48] A Phase 1 Trial of Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory CD22+B-Cell Acute Lymphoblastic Leukemia
    Jain, Nitin
    Jabbour, Elias J.
    Konopleva, Marina
    Pemmaraju, Naveen
    Thompson, Philip A.
    Short, Nicholas J.
    Kadia, Tapan M.
    Borthakur, Gautam
    Daver, Naval
    DiNardo, Courtney D.
    Aldoss, Ibrahim
    Cook, Robin
    Ravandi, Farhad
    Kantarjian, Hagop
    BLOOD, 2021, 138
  • [49] Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL)
    Bartlett, N.
    Forero-Torres, A.
    Rosenblatt, J.
    Fanale, M.
    Horning, S. J.
    Thompson, S.
    Sievers, E. L.
    Kennedy, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial
    Jain, Nitin
    Jabbour, Elias
    Aldoss, Ibrahim
    Konopleva, Marina
    Short, Nicholas
    Stein, Anthony S.
    Pemmaraju, Naveen
    Thompson, Philip A.
    Ravandi, Farhad
    Kantarjian, Hagop
    BLOOD, 2022, 140
12345